The correlation between adverse events and survival benefits of donafenib in the first-line treatment of advanced hepatocellular carcinoma

作者全名："Bi, F.; Qin, S.; Xu, J.; Du, C.; Fan, Q.; Zhang, L.; Tao, M.; Jiang, D.; Wang, S.; Chen, Y.; Sheng, J.; Zhuang, X.; Wu, J.; Liu, L."

作者地址："[Bi, F.] Sichuan Univ, West China Hosp, Dept Med Oncol, Chengdu, Peoples R China; [Qin, S.] Jinling Hosp, PLA Canc Ctr Nanjing, Nanjing, Peoples R China; [Xu, J.] Peoples Liberat Army Gen Hosp, Dept Med Oncol, Med Ctr 5, Beijing, Peoples R China; [Du, C.] Chongqing Med Univ, Affiliated Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China; [Fan, Q.] Zhengzhou Univ, Affiliated Hosp 1, Dept Oncol, Zhengzhou, Peoples R China; [Zhang, L.] Xuzhou Med Univ, Affiliated Hosp, Dept Radiotherapy, Xuzhou, Jiangsu, Peoples R China; [Tao, M.] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China; [Jiang, D.] Hebei Med Univ, Hosp 4, Dept Med Oncol, Shijiazhuang, Hebei, Peoples R China; [Wang, S.] Southern Med Univ, Zhujiang Hosp, Dept Oncol, Guangzhou, Peoples R China; [Chen, Y.] Wenzhou Med Univ, Affiliated Hosp 1, Dept Infect & Liver Dis, Wenzhou, Peoples R China; [Sheng, J.] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Dept Infect Dis, Hangzhou, Peoples R China; [Zhuang, X.] Shantou Univ, Coll Med, Canc Hosp, Dept Intervent Therapy, Shantou, Peoples R China; [Wu, J.] First Peoples Hosp Changzhou, Dept Oncol, Changzhou, Jiangsu, Peoples R China; [Liu, L.] Suzhou Zelgen Biopharmaceut Co Ltd, Suzhou, Peoples R China"

通信作者：　

来源：ANNALS OF ONCOLOGY

ESI学科分类：CLINICAL MEDICINE

WOS号：WOS:000670004200089

JCR分区：Q1

影响因子：50.5

年份：2021

卷号：32

期号：　

开始页：S128

结束页：S128

文献类型：Meeting Abstract

关键词：　

摘要：　

基金机构：Zelgen

基金资助正文：Zelgen.